PALB2 and medical procedure: Moreover, this review was limited to Tier 1 conditions-future research and evidence synthesis will be needed to address other actionable gene-condition pairs (e.g., other genes for hereditary breast and ovarian cancer including PALB2, RAD51C, RAD51D, and BRIP1 (Manchanda et al., 2018); TTR for hereditary transthyretin amyloidosis (Soper et al., 2021); endocrine tumour genes (Savatt et al., 2022); arrhythmia syndrome genes (Walsh et al., 2022)) and their suitability for population genomic screening.